Last updated on February 2018

PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Poorly Differentiated Thyroid Carcinoma
  • Age: Between 18 - 70 Years
  • Gender: Male or Female

Inclusion Criteria:

  1. Volunteer to participate and sign the informed consent form;
  2. Age :18-70 years old;
  3. Histopathologically confirmed inoperable advanced poorly differentiated thyroid carcinoma;
  4. Previously received surgery, I131 treatment, radiotherapy, chemotherapy patients can be enrolled
  5. At least one measurable lesion according to the solid tumor efficacy evaluation criteria (RECIST 1.1);
  6. Expected survival time 3 months;
  7. Karnofsky score 70;
  8. Blood testANC 1.5109/L PLT 75109/LHb 90g/L;
  9. Liver function:Serum bilirubin (SB) level: normal upper limitULN2 times; aspartate aminotransferase(AST) and alanine aminotransferase(ALT) ULN 2.5times; or ULN 5times if Liver metastases are present;
  10. Renal function: Serum creatinine ULN 1.5times;
  11. LVEF 50%;
  12. No serious complications such as active digestive tract hemorrhage, perforation, jaundice, gastrointestinal obstruction, noncancerous fever > 38;
  13. Subjects are well-behaved, able to undergo the follow-up efficacy and adverse reactions according to the program requirements.

Exclusion Criteria:

  1. Active or uncontrolled severe infection (CTCAE grade 2 infection)
  2. Previously received anthracycline-based regimen: the cumulative dose of doxorubicin at or above 500 mg / m2 or the cumulative dose of epirubicin reached or exceeded 800 mg / m2;
  3. The New York Heart Association (NYHA) graded class II or above heart disease patients previously or at present;
  4. Patients with CNS disorders or CNS metastases;
  5. Allergic to chemotherapeutic drugs or their excipients or intolerant patients;
  6. Received any other test drug treatment within 30 days of the first chemotherapy administration;
  7. Pregnant or lactating women;
  8. Arterial/venous thrombosis occurred within 6 months, such as cerebrovascular accident (including transient ischemic attack), deep venous thrombosis, and pulmonary embolism;
  9. History of aneurysm;
  10. Neurological disorders with a history of epilepsy or ataxia require treatment;
  11. A history of drug abuse and incapable of abstinence or mental disorder;
  12. A history of peripheral neuropathy and the muscle strength is below level 3;
  13. Suffering from other diseases and complications of hand-foot syndrome;
  14. Researchers think it is not suitable for enrolling.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.